Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$182.5M
31M shares
52-week range
$5.23 – $50.40
1% from low
Sector
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Exchange
NASDAQ
CS
Borrow rate
0.69%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $15.0M | $0 | $0 | $19.1M |
| Cost of revenue | $0 | $121.0K | $734.0K | $0 | $0 | $58.0K | $705.0K |
| Gross profit | $0 | −$121.0K | −$734.0K | $15.0M | $0 | −$58.0K | $18.4M |
| Gross margin | — | — | — | 100.0% | — | — | 96.3% |
| R&D | $0 | $9.1M | $37.9M | $21.1M | $59.5M | $29.8M | $18.7M |
| Operating income | −$29.0K | −$13.5M | −$60.4M | −$10.5M | −$72.4M | −$58.6M | −$91.1M |
| EBITDA | $142.9K | −$68.2M | −$70.0M | −$10.5M | −$70.1M | −$49.7M | −$81.3M |
| Net income | −$109.0K | −$68.4M | −$70.8M | −$10.8M | −$70.0M | −$49.8M | −$82.1M |
| Net margin | — | — | — | -72.1% | — | — | -430.3% |
| EPS (diluted) | -0.01 | -8.24 | -8.54 | -12.89 | -15.30 | -2.34 | -2.85 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $19M | $-4.56 | $-5.50–$-3.51 | 6 |
| 2027 | $65M | $-3.47 | $-4.93–$-1.53 | 6 |
| 2028 | $135M | $-1.66 | $-4.09–$1.57 | 4 |
| 2029 | $264M | $1.41 | $0.46–$2.32 | 2 |
Forward consensus · source: Financial Modeling Prep
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
www.lenz-tx.comNo one on the platform currently holds LENZ.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2024-12-31 | 25,366 | $732.3K |
| Execution date | Ratio |
|---|---|
| 2024-03-22 | 1-for-7reverse |
No one on the platform has traded LENZ yet.
| $1.7B |
| — |
| NBTXNanobiotix S.A. | $35.99 | +4.53% | $1.8B | — |
| PRMEPrime Medicine, Inc. | $3.43 | +7.86% | $620M | — |
Source: Financial Modeling Prep · peers by sector/industry
$LENZ this company should have never been public...it was RA Capital's stupid bet and they kept throwing money at it to rescue themselves.... now they are in Memento and will do the same. They need to be banned from using public markets as an exit for their companies that no pharma wants to buy
View on StockTwits ↗$NVDA $SPY this company $LENZ is trading at $5.56...$5 put options selling for $0.10 lol
View on StockTwits ↗$LENZ so much pain, I have been upgraded to long term investor lmao 😭
View on StockTwits ↗$LENZ Insiders have been buying again. Believe they know the value of their company.
View on StockTwits ↗$LENZ Trading well below book value now. Somebody might do a hostile takeover.
View on StockTwits ↗$LENZ Worldwide sales could easily top the market cap. And at eighty percent profit margin shorts are playing with fire.
View on StockTwits ↗$LENZ post-earnings this will be sub $5.... really bad what RA Capital and Sequoia did to retail
View on StockTwits ↗$LENZ if you haven’t been shorting this stock then you don’t like money. We will see $3-4 here soon.
View on StockTwits ↗$LENZ sales numbers are going to be very disappointing....also look at the SG&A expenses
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.